DUBLIN - Endo International plc (OTC: OTC:ENDPQ) through its subsidiary Par Pharmaceutical, Inc., has recently launched a generic version of the medication DUEXIS®, which combines ibuprofen and famotidine.
This new product is designed to treat symptoms of rheumatoid arthritis and osteoarthritis while reducing the risk of stomach and upper intestinal ulcers that can result from ibuprofen use.
The company's Senior Vice President and General Manager, Scott Sims, emphasized Endo's commitment to offering affordable healthcare options and maintaining its status as a dependable supplier of quality pharmaceuticals.
The generic combination medication, consisting of 800 mg of ibuprofen and 26.6 mg of famotidine, is reported to have generated sales of approximately $49 million over the 12 months ending December 31, 2023, according to data from IQVIA™.
This release is based on a press release statement from Endo International plc.
InvestingPro Insights
In the midst of Endo International's launch of a generic version of DUEXIS®, the company's financial health and stock performance are crucial for investors monitoring the pharmaceutical sector. According to real-time data from InvestingPro, Endo International has a market capitalization of just $0.12 million, underscoring the company's significantly reduced valuation. Despite a challenging period, the company managed to generate revenue of $2011.52 million in the last twelve months as of Q4 2023, although this represents a decrease of 13.25% compared to the previous period.
InvestingPro Tips reveal that Endo International's stock has experienced significant return over the last week, with a price total return of 66.67%. However, it's important to note that the stock generally trades with high price volatility and has seen a dramatic 99.41% decrease in its one-year price total return. Analysts on InvestingPro predict that the company will be profitable this year, which could be a pivotal factor for the stock's future trajectory.
For investors seeking more comprehensive analysis, the InvestingPro platform offers additional insights into Endo International, including an in-depth look at company fundamentals and expert forecasts. With the use of the exclusive coupon code PRONEWS24, investors can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, gaining access to a total of 9 InvestingPro Tips for Endo International.
As Endo International strives to expand its product line and offer cost-effective solutions in the healthcare market, these financial metrics and expert insights can provide valuable context for investors considering the company's prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.